Jefferies 3rd Annual Healthcare Conference

1

• Jefferies 3rd Annual Healthcare Conference
• June 17, 2009
• Glenn P. Muir
• EVP CFO

2
Forward-Looking Statements

• This presentation contains forward-looking
  information that involves risks and
  uncertainties, including statements regarding the
  Companys plans, objectives, expectations and
  intentions. Such statements include, without
  limitation, statements regarding the Companys
  expectations regarding Fiscal 2009 results, and
  the expected continued market challenges and the
  Companys response to those challenges. These
  forward-looking statements are based upon
  assumptions made by the Company as of the date
  hereof and are subject to known and unknown risks
  and uncertainties that could cause actual results
  to differ materially from those anticipated.
  Factors that could adversely affect the Companys
  business and prospects are described in the
  Companys filings with the Securities and
  Exchange Commission. Hologic expressly disclaims
  any obligation or undertaking to release publicly
  any updates or revisions to any such statements
  to reflect any change in the Companys
  expectations or any change in events, conditions
  or circumstances on which any such statement is
  based.

2
3
Use of Non-GAAP Financial Measures

• In addition to the financial measures prepared in
  accordance with generally accepted accounting
  principles (GAAP), we use the non-GAAP financial
  measure adjusted EPS. The Company generally
  defines its non-GAAP adjusted EPS to exclude the
  non-cash amortization of intangible assets
  acquired by the Company since 2006 or impairment
  of goodwill and intangible assets, other
  acquisition related charges, such as charges
  associated with the write-up of acquired
  inventory to fair market value, and other
  one-time, non-recurring, unusual or unanticipated
  charges, expenses or gains and tax
  provisions/benefits related thereto. Adjusted EPS
  is not a measure of operating performance under
  GAAP. We believe the use of this non-GAAP measure
  helps investors to gain a better understanding of
  our core operating results and future prospects,
  consistent with how management measures and
  forecasts our performance, especially when
  comparing such results to previous periods or
  forecasts. When analyzing our operating
  performance, investors should not consider this
  non-GAAP measure as a substitute for EPS prepared
  in accordance with GAAP.

3
4
THE Global Leader in Womens Health
T H E C O N C E P T O F H O L O G I C
4
5
Best-In-Class Products

• Screening
• Diagnosis
• Intervention
• Early DetectionSaves Lives

ThinPrep Pap TestCervical Cancer
Screening CerVista HPV Test
MammoSiteRadiation Therapy

ThinPrep Imaging Cervical Cancer Screening
DiscoveryOsteoporosisScreening
Suros Biopsy Systems

FullTerm Preterm Labor
NovaSure Endometrial Ablation
MultiCareStereotactic Biopsy
Selenia Breast Cancer Screening
AdianaPermanent Contraception
5
6
Leading Market Positions Include
Ranking in U.S.
Breast cancer screening
Cervical cancer screening
Preterm labor screening
Abnormal uterine bleeding
Osteoporosis screening
Radiation therapy, partial-breast
Biopsy
6
7
Largest Dedicated Womens Health Sales Force in
U.S
Over 460US Sales Representatives
ensures best-in-classbrand recognition
7
8
And Broad International Distribution

• 125 countries

• 200 sales force

• 150 distributors

Going global leverage distribution
cross-selling
8
9
An Impressive Growth Record MeetsCurrent
Economic Slowdown
Revenue (M)
Income from Operations(M)
1,625 - 1,650
490 - 505
Adjusted excluding acquisition-related charges
Note Fiscal Year ends last Saturday in September
9
10
Four Focused Business Segments
Breakdown of Q2-09 Revenues of 402.0M
33Diagnostics
135.0M
Disposables 58 Capital Equip 42
180.1M
45Breast Health
63.8.0M
16GYN Surgical
23.1M
6Skeletal Health
10
11
Existing Products Sustained Growth and Momentum
Key Products Fueling Growth in U.S.
EstimatedU.S. Market
Estimated U.S. Future Market
Product
Application
Selenia/ Tomosynthesis
Breast cancerscreening
600M
1B
ThinPrep/ Cervista HPV
Cervical cancerscreening
700M
1B
Endometrialablation
300M
1.5B
NovaSure
Adiana
100M
1B
Contraception
Suros ATEC, Eviva and Celero
250M
500M
Biopsy systems
Preterm labor risk test
100M
300M
FullTerm
Awaiting PMA approval for U.S. market
11
12
New Products Molecular Diagnostics Platform

• FDA Approvals of Two Products in March 2009
• Cervista HPV HR (high risk)
• Designed to detect the 14 high-risk types of HPV
  that cause cervical cancer
• First HPV DNA test approved by the FDA in more
  than 10 years
• Cervista HPV 16/18
• First HPV test approved for genotyping for HPV
  types 16 and 18
• Associated with 70 of all cervical cancers in
  the U.S.
• The HPV Market
• 400M U.S. 50 penetrated
• 400M O.U.S. 10 penetrated
• Complementary with ThinPrep Pap test
• Invader Chemistry
• Platform for entry into 2.1B U.S. molecular
  market
• Strong pipeline of products - Chlamydia,
  Gonorrhea
• Utilizes existing sales channel
• Accretive to non-GAAP EPS in FY 2010

13
New Products Adiana Permanent Contraception
System
Primary market Patients undergoing tubal
ligation (excluding post C-section) Secondary
market The longer term and larger group of women
using hormones
Est. U.S. Future Market 1B
Est. Population
Total U.S. Women with Two or More Children on
Birth Control
Delivery Catheter
Total Sterilization Surgeries
Matrix
Initial Target
Adiana will be one of the only two products on
the market
Awaiting FDA approval for U.S. market
14
New Products Next Generation Digital Mammography
Selenia Dimensions Digital Mammography

• 3D visualization of breast tissue multiple
  views
• Helps solve tissue overlap problems
• Improved detection and lower recall rates
• Currently working with FDA (expect to be
  first-to-market)
• International launch in September 2008

Normal Mammogram
Tomosynthesis Slices
Work-in-Progress Awaiting FDA approval
14
15
Why Invest in Hologic
I N S U M M A R Y THANK YOU!
MarketLeadership
Leading global player inwomens healthcare
FinancialStrength
Innovative New Products
Market Growth
Broad Distribution
15